Bellevue Group AG Makes New Investment in Roivant Sciences Ltd. (NASDAQ:ROIV)

Bellevue Group AG bought a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 24,000 shares of the company's stock, valued at approximately $284,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Norges Bank purchased a new position in Roivant Sciences during the 4th quarter worth approximately $52,443,000. Invesco Ltd. boosted its holdings in Roivant Sciences by 49.7% in the fourth quarter. Invesco Ltd. now owns 9,515,058 shares of the company's stock worth $112,563,000 after purchasing an additional 3,159,603 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Roivant Sciences by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock valued at $521,553,000 after acquiring an additional 2,404,232 shares during the last quarter. TOMS Capital Investment Management LP raised its position in shares of Roivant Sciences by 46.6% in the fourth quarter. TOMS Capital Investment Management LP now owns 5,885,000 shares of the company's stock valued at $69,620,000 after purchasing an additional 1,870,000 shares during the period. Finally, Marshall Wace LLP lifted its position in Roivant Sciences by 104.4% during the 4th quarter. Marshall Wace LLP now owns 2,946,954 shares of the company's stock worth $34,862,000 after acquiring an additional 1,505,062 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Monday, April 21st.

Roivant Sciences Trading Down 1.3 %

NASDAQ ROIV traded down $0.14 during trading hours on Thursday, reaching $11.03. 5,804,697 shares of the company's stock were exchanged, compared to its average volume of 5,543,262. The firm has a fifty day moving average of $10.46 and a 200-day moving average of $11.12. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $13.06. The stock has a market cap of $7.87 billion, a PE ratio of -73.53 and a beta of 1.23.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, research analysts forecast that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Insider Activity

In related news, COO Eric Venker sold 100,000 shares of the firm's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $10.22, for a total value of $1,022,000.00. Following the transaction, the chief operating officer now owns 1,116,345 shares in the company, valued at $11,409,045.90. This trade represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the sale, the chief accounting officer now owns 163,264 shares of the company's stock, valued at approximately $1,702,843.52. This represents a 58.22 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,395,541 shares of company stock valued at $14,922,538. Company insiders own 7.90% of the company's stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.